Nasal congestion

Positive Results of EfficAPSI Real-World Study Confirm Significant Benefit of Sublingual Liquid AIT Treatment on the Onset and Worsening of Asthma in Patients With Allergic Rhinitis

Retrieved on: 
Saturday, July 2, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Managed Care, Diagnosis, LEN, Knowledge, Patient, Allergy, III, Agache, Czech Republic, ARIA, Nose, HDR, Itchy, Nasal congestion, AIT, EAACI, Paris Diderot University, Allergen, The Journal of Allergy and Clinical Immunology, Shyam Swarup Agarwal, Internal medicine, Allergic rhinitis, Disease, Sneeze, Public health, Water, Atopy, Profile, World, Risk, European Academy of Allergy and Clinical Immunology, MITES, World Health Organization, Doctor of Philosophy, Pulmonology, Time, House, Congress, Pharmacy, MD, Therapy, Pharmaceutical industry, Perfume, Asthma

Presented at the 2022 European Academy of Allergy and Clinical Immunology (EAACI) congress in Prague (Czech Republic), the real-world study confirmed significant benefit of sublingual liquid allergen immunotherapy treatment (AIT) on the onset and worsening of asthma in patients with allergic rhinitis.

Key Points: 
  • Presented at the 2022 European Academy of Allergy and Clinical Immunology (EAACI) congress in Prague (Czech Republic), the real-world study confirmed significant benefit of sublingual liquid allergen immunotherapy treatment (AIT) on the onset and worsening of asthma in patients with allergic rhinitis.
  • The primary objective of the study was the evaluation of the impact of sublingual liquid AIT on the onset and worsening of asthma in patients with allergic rhinitis.
  • The results of the EfficAPSI real-world study confirm and broaden the findings of randomised clinical trials and strengthen the body of evidence of the positive impact of sublingual liquid AIT on the onset and worsening of allergic asthma in patients with allergic rhinitis.
  • Its objective is to evaluate the real life impact of sublingual liquid allergen immunotherapy on the onset and worsening of asthma in patients with allergic rhinitis.

Four-Year Results Show Aerin Medical’s VivAer® Treatment Provides Significant, Sustained Relief of Nasal Obstruction Symptoms

Retrieved on: 
Wednesday, June 29, 2022
Health, Medical Devices, Surgery, Clinical Trials, Research, Science, Biotechnology, International Forum of Allergy & Rhinology, FDA, NAO, Patient, LinkedIn, Nose, CEO, Nasal congestion, Allergy, ENT, Population, Exercise, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, NVC, YouTube, Otorhinolaryngology, Technology, CE marking, Freezing, Prevalence, Hofstra University, Ear, Instagram, Network congestion, Solution, Safety, Twitter, Physician, Multimedia, Norwegian Asthma and Allergy Association, Pharmaceutical industry, Facebook

The results showed the long-term durability of VivAer treatment for those with nasal airway obstruction (NAO) due to nasal valve collapse (NVC).

Key Points: 
  • The results showed the long-term durability of VivAer treatment for those with nasal airway obstruction (NAO) due to nasal valve collapse (NVC).
  • In the follow-up study, patients experienced significant and sustained improvement in symptoms of NAO through four years following a single treatment of NVC with VivAer.
  • View the full release here: https://www.businesswire.com/news/home/20220629005192/en/
    Following treatment with VivAer, published data demonstrate significant and sustained improvement in symptoms of nasal airway obstruction due to nasal valve collapse through four years.
  • VivAer, a non-invasive technology developed by Aerin Medical Inc., uses temperature-controlled radiofrequency energy to provide long-term relief from nasal obstruction symptoms.

At 6.9% CAGR, Global Erectile Dysfunction Drugs Market Size & Share Will Hit US$ 5.94 Billion | Industry Trends, Demand, Growth, Value, Analysis & Forecast Report by Zion Market Research

Retrieved on: 
Wednesday, June 22, 2022
Erectile dysfunction, CAGR, Population, Therapy, Obesity, Fear, Smoking, Cardiovascular disease, Alcoholism, Dizziness, Nasal congestion, Research, Severe cognitive impairment, Man, Adoption, Projection, OPC Historical Data Access, USD, Rash, Flushing, Marketing, Investment, Diarrhea, Sale, ED, Patient, Medicine, Strategic management, Awareness, Headache, Male, Diabetes, Risk, Dietary supplement, Pharmaceutical industry, Apomorphine, Prostaglandin E1, Tadalafil

Key Industry Insights & Finding of the Erectile Dysfunction Drugs Market Reports:

Key Points: 
  • Key Industry Insights & Finding of the Erectile Dysfunction Drugs Market Reports:
    As per the analysis shared by our research analyst, the Erectile Dysfunction Drugs Market is expected to grow annually at a CAGR of around 6.9 % (2022-2028).
  • Erectile dysfunction drugs are majorly sold in developed and emerging economies; however, the percentage of their sale is less in low- and middle-income countries.
  • Furthermore, increased investments in advertisements are also likely to contribute significantly to the expansion of the global erectile dysfunction drugs market.
  • The expanding manufacture of generic erectile dysfunction pharmaceuticals, as well as the growing availability of bogus erectile dysfunction drugs, are two important challenges for the market.

At 6.9% CAGR, Global Erectile Dysfunction Drugs Market Size & Share Will Hit US$ 5.94 Billion | Industry Trends, Demand, Growth, Value, Analysis & Forecast Report by Zion Market Research

Retrieved on: 
Wednesday, June 22, 2022
Erectile dysfunction, CAGR, Population, Therapy, Obesity, Fear, Smoking, Cardiovascular disease, Alcoholism, Dizziness, Nasal congestion, Research, Severe cognitive impairment, Man, Adoption, Projection, OPC Historical Data Access, USD, Rash, Flushing, Marketing, Investment, Diarrhea, Sale, ED, Patient, Medicine, Strategic management, Awareness, Headache, Male, Diabetes, Risk, Dietary supplement, Pharmaceutical industry, Apomorphine, Prostaglandin E1, Tadalafil

Key Industry Insights & Finding of the Erectile Dysfunction Drugs Market Reports:

Key Points: 
  • Key Industry Insights & Finding of the Erectile Dysfunction Drugs Market Reports:
    As per the analysis shared by our research analyst, the Erectile Dysfunction Drugs Market is expected to grow annually at a CAGR of around 6.9 % (2022-2028).
  • Erectile dysfunction drugs are majorly sold in developed and emerging economies; however, the percentage of their sale is less in low- and middle-income countries.
  • Furthermore, increased investments in advertisements are also likely to contribute significantly to the expansion of the global erectile dysfunction drugs market.
  • The expanding manufacture of generic erectile dysfunction pharmaceuticals, as well as the growing availability of bogus erectile dysfunction drugs, are two important challenges for the market.

Aerin Medical Secures $60 Million in Equity Financing

Retrieved on: 
Thursday, June 16, 2022
Biotechnology, Finance, Surgery, General Health, Health, Medical Devices, Professional Services, Other Health, Solution, Population, Network congestion, Nasal congestion, CEO, Questa, New Mexico, CIO, ENT, KCK, LinkedIn, Growth, RVNG Intl., Physician, YouTube, World Bank, Quality of life, Nose, Twitter, Patient, Sichuan Road and Bridge Group, Multimedia, Instagram, Medtech, Ear, Pharmaceutical industry, Management, Facebook

Aerin Medical Inc. , a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced it has recently closed a $60 million equity financing.

Key Points: 
  • Aerin Medical Inc. , a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced it has recently closed a $60 million equity financing.
  • View the full release here: https://www.businesswire.com/news/home/20220616005128/en/
    Aerin Medical closed a $60 million equity financing led by new investor Ally Bridge Group, with all existing major investors KCK MedTech, Questa Capital and OrbiMed participating.
  • Aerin Medical is a privately held, venture-backed company, with U.S. offices in California and Texas.
  • For more information, please visit www.aerinmedical.com and follow Aerin Medical on Facebook , Twitter , Instagram , LinkedIn and YouTube .

Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis 

Retrieved on: 
Monday, June 13, 2022
People, Vaccination, Allergic rhinitis, Nasal congestion, Eosinophil, Allergen, EMA, Nose, Forward-looking statement, Immunity, Disease, Sneeze, SPAC, Allergy, Revelation, Degenerative disease, Basophil, FDA, Media, Polyp (medicine), GLOBE, Patient, Private Securities Litigation Reform Act, Risk, Trial of the century, COVID-19, Atmosphere, Quality of life, NASDAQ, SEC, T helper cell, SAN, Sinusitis, CCR3, Safety, Pharmaceutical industry, Online shopping, Vaccine

Allergic rhinitis, or hay fever, is an allergic reaction to tiny particles in the air called allergens.

Key Points: 
  • Allergic rhinitis, or hay fever, is an allergic reaction to tiny particles in the air called allergens.
  • Allergic rhinitis can lead to complications in some cases including nasal polyps, sinusitis, and middle ear infections.
  • Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.
  • REVTx-99b, the lead therapeutic candidate, is being developed for allergic rhinitis, and is currently being evaluated as a treatment for allergic rhinitis in a Phase 1b CLEAR study.

Aerin Medical’s RhinAer® Demonstrates Long-term Safety and Efficacy for Treatment of Chronic Rhinitis in Newly Published Two-year Study

Retrieved on: 
Tuesday, June 7, 2022
Biotechnology, Health, Medical Devices, Allergic rhinitis, Nasal congestion, PNN, Chronic cough, Otorhinolaryngology, ENT, Nose, International Forum of Allergy & Rhinology, Sneeze, Ear, Solution, Multimedia, Rhinitis, Physician, Allergy, Patient, Technology, RF, MD, Safety, Rhinorrhea, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20220607005151/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220607005151/en/
    Two-year data published online in Allergy & Rhinology confirms that treatment with RhinAer provides significant and lasting improvement of chronic rhinitis symptoms.
  • RhinAer, a non-invasive technology developed by Aerin Medical Inc., uses temperature-controlled radiofrequency energy to provide long-term relief from chronic rhinitis.
  • Treatment of the PNN using RhinAer has been shown to be an effective, patient-friendly option to treat both chronic allergic and non-allergic rhinitis.
  • RhinAer provides ENTs a compelling alternative with lasting benefits for appropriate chronic rhinitis patients whether they suffer from allergic or non-allergic rhinitis.

SinuSonic Announces Presentation of Double-Blind, Sham-Controlled Trial Data Showing Regular Use of the Device Improved Nasal Congestion

Retrieved on: 
Thursday, May 26, 2022
Allergy, Population, Patient, Quality of life, TSS, Medical school, URI, Research, FDA, Nasal congestion, Administration, LLC, Medical University of South Carolina, GLOBE, Pharmaceutical industry

"This study was discussed during an oral podium presentation at the American Rhinological Society Spring meeting in Dallas, Texas, on April 28-29, 2022.

Key Points: 
  • "This study was discussed during an oral podium presentation at the American Rhinological Society Spring meeting in Dallas, Texas, on April 28-29, 2022.
  • This study showed, with the highest level of evidence, a randomized sham-controlled study that regular use of the active SinuSonic device improved nasal congestion.
  • Administration of acoustic vibration and oscillating expiratory positive pressure with SinuSonic has been shown in a prior study to improve nasal congestion and air flow.
  • It has been estimated that the financial impact of chronic nasal congestion is more than $5 - 10 billion annually.

Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis

Retrieved on: 
Monday, May 23, 2022
People, Risk, Disease, Allergy, Polyp (medicine), Sneeze, Private Securities Litigation Reform Act, Polyp, Degenerative disease, CCR3, Patient, Revelation, NASDAQ, Quality of life, Sinusitis, COVID-19, Trial of the century, Vaccination, FDA, SAN, Media, Nasal congestion, SMC, Allergic rhinitis, Atmosphere, EMA, Immunity, SPAC, Forward-looking statement, Safety, T helper cell, Eosinophil, Nose, Mouth, SEC, Allergen, Network congestion, GLOBE, Pharmaceutical industry, Online shopping, Vaccine

The primary endpoint is to evaluate the effects of REVTx-99b versus placebo on safety and tolerability.

Key Points: 
  • The primary endpoint is to evaluate the effects of REVTx-99b versus placebo on safety and tolerability.
  • Key secondary endpoints include allergy symptoms (Total Nasal Symptom Score) and peak nasal inspiratory flow elicited by nasal allergen challenge.
  • Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.
  • REVTx-99b, the lead therapeutic candidate, is being developed for allergic rhinitis, and is currently being evaluated as a treatment for allergic rhinitis in a Phase 1b CLEAR study.

Beekeeper's Naturals Introduces Propolis-Powered Sinus Support & Nasal Spray

Retrieved on: 
Monday, May 23, 2022
People, Inflammation, Quercetin, Dry, Environment, Multimedia, Science, Solution, Health, Propolis, Irritant, Histamine, Xylitol, Research, Southern Beekeeper's Nature Reserve, Awareness, Nasal congestion, Bee, Mucus, Natural, CEO, Beekeeping

NEW YORK, May 23, 2022 /PRNewswire/ -- Revolutionizing the health and wellness category, Beekeeper's Naturals announces the launch of their propolis-powered Sinus Support Collection - Sinus Support, a potent dose of seasonal sinus care that supports healthy histamine levels, and Nasal Spray to help clear nasal congestion while gently soothing and moisturizing the nasal passages. This leading innovation represents Beekeeper's Naturals next step in creating clean and effective alternatives, powered by propolis and backed by science.

Key Points: 
  • NEW YORK, May 23, 2022 /PRNewswire/ -- Revolutionizing the health and wellness category, Beekeeper's Naturals announces the launch of their propolis-powered Sinus Support Collection - Sinus Support, a potent dose of seasonal sinus care that supports healthy histamine levels, and Nasal Spray to help clear nasal congestion while gently soothing and moisturizing the nasal passages.
  • "We're thrilled to extend our propolis-powered collection with the launch of the Sinus Support Collection.
  • Key ingredient propolis provides relief from nasal and sinus congestion, irritants, post nasal drip and dryness while xylitol soothes the nasal tissue, increases the flow of mucus and increases nasal volume to increase air flow through the nasal passage.
  • Beekeeper's Naturals Sinus Support ($31.99) and Nasal Spray ($13.99) are suitable for ages 12+.